BIENAIME JEAN JACQUES 4

What Happened
Jean Jacques Bienaime, a director of Keros Therapeutics, acquired 1,000 shares in open-market purchases on June 15, 2026. The reported weighted-average price was $10.19 per share for a total cash outlay of $10,190. This was a purchase (insider buy) rather than a sale.

Key Details

• Transaction date: 2026-06-15 (reported on Form 4 filed 2026-06-17; filing appears timely).
• Transaction type/code: Open market purchase (P).
• Shares purchased: 1,000; weighted-average price: $10.19; total value ≈ $10,190.
• Price range: purchases occurred at prices between $9.99 and $10.34 (weighted average reported). The filer offers to provide a breakdown of how many shares were bought at each price upon request.
• Footnote: Shares purchased pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.
• Shares owned after transaction: Not specified in this filing.

Context
Insider purchases are often watched by retail investors as a potential sign of confidence, but they can also occur under pre-set 10b5-1 plans that schedule trades in advance. This purchase was executed under such a plan (adopted 12/05/2025), which can reduce the extent to which the trade reflects new, real-time insider sentiment.